Hydrosome Labs, a US biotechnology company focused on ultrafine bubble (UFB) technology, on Tuesday reported new findings from a study with Biocell Energetics, a venture from the University of Birmingham in the UK.
According to Hydrosome, the research demonstrated that winemaking/brewing yeast (Saccharomyces bayanus) grown in media infused with UFB water exhibited faster glucose metabolism and as much as a 31% increase in oxygen uptake rates compared to conventional fermentation using deionised water. These results suggest that Hydrosome Technology can significantly increase production output without requiring costly infrastructure changes.
The study involved real-time oxygen consumption monitoring and glucose utilisation tracking of UFBs on yeast respiration and metabolic performance. Findings include: a 31% increase in peak oxygen uptake at high UFB concentrations and 22% at medium levels versus a control without UFBs; up to 6X faster initial glucose consumption compared to the control; and a clear dose-response effect between UFB concentration and respiratory performance.
These results build on a 400-litre pilot study by Hydrosome Labs and the University of Illinois on E. coli fermentation, in which continuous UFB infusion doubled cell output, accelerated doubling time, and improved glucose utilisation by nearly threefold. That study also recorded a 14% increase in oxygen uptake, further validating UFBs as a tool for improving fermentation efficiency.
Hydrosome Labs says that it is partnering with companies across industries, including precision fermentation, functional beverages, and personal care, to scale these benefits through clean-label, chemical-free delivery systems.
Orion Pharma launches Phase 1b/2 TEADCO trial of ODM-212 in advanced solid tumours
Natera showcases Prospera transplant data across 17 presentations at ISHLT 2026
AstraZeneca reports third positive Phase III trial for tozorakimab in COPD
Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026
Whitehawk Therapeutics presents ADC preclinical data at AACR 2026
European Commission approves Merck's ENFLONSIA for infant RSV prevention in Europe
Philips secures FDA clearance for Spectral CT Verida system
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
hVIVO signs influenza human challenge trial agreement with Traws Pharma
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer
GSK secures China approval for Exdensur to treat nasal polyp condition
Dexcel Pharma's Nintedanib Capsules approved for US launch
Gilead to acquire Tubulis to expand ADC oncology capabilities
Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP